[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100554075":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":31,"responsibleParty":48,"collaborators":50,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":20,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":20,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Ruijin Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Chimeric antigen receptor T cells LCAR-HL30 cells","EXPERIMENTAL","Each subject will receive LCAR-HL30 cells.",[13],"Biological: LCAR-HL30 cells",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","LCAR-HL30 cells","Prior to infusion of the LCAR-HL30, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Jianqing Mi","CONTACT","13524488296","jianqingmi@shsmu.edu.cn",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},"Wenyan Yu","13564230293","ywy01778@rjh.com.cn",[32],{"facility":33,"status":34,"city":35,"state":20,"zip":20,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","RECRUITING","Shanghai","China","CN",{"type":39,"coordinates":40},"Point",[41,42],121.45806,31.22222,{"lat":42,"lon":41},[45,46],{"name":28,"role":24,"phone":20,"phoneExt":20,"email":20},{"name":23,"role":47,"phone":20,"phoneExt":20,"email":20},"PRINCIPAL_INVESTIGATOR",{"type":49,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[51],{"name":52,"class":53},"Nanjing Legend Biotech Co.","INDUSTRY","100554075","phase-1-a-study-of-lcar-hl30-in-subjects-with-relapsedrefractory-hodgkins-lymphoma-and-anaplastic-large-cell-lymphoma-100554075",false,"NCT06494371","A Study of LCAR-HL30 in Subjects With Relapsed\u002FRefractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma","An Open-label Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of CD30-Targeted LCAR-HL30 Cells in Patients With Relapsed\u002FRefractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma","Inclusion Criteria:\n\n1. Subjects voluntarily participate in clinical research.\n2. Aged 18 to 75 years, either sex.\n3. Eastern Cooperative Oncology Group (ECOG) score 0-1 (Dose escalation phase). ECOG score 0-2 (Dose expansion period).\n4. Histologically confirmed Hodgkin's lymphoma or Anaplastic large cell lymphoma with positive CD30 expression.\n5. At least one evaluable tumor lesion according to Lugano 2014 criteria.\n6. Expected survival ≥3 months.\n7. Clinical laboratory values in the screening period meet criteria.\n8. Effective contraception.\n\nExclusion Criteria:\n\n1. Prior antitumor therapy with insufficient washout period.\n2. Previous treatment with CAR-T therapy, allogeneic hematopoietic stem cell transplantation.\n3. Severe underlying diseases;\n4. Hepatitis B virus surface antigen (HbsAg), Hepatitis B virus deoxyribonucleic acid (HBV DNA), hepatitis C virus ribonucleic acid (HCV RNA) or human immunodeficiency virus antibody (HIV-Ab) positive.\n5. Presence of other serious pre-existing medical conditions that may limit patient participation in the study. Any condition that, in the investigator's judgment, will make the subject unsuitable for participation in this study.","ALL","18 Years","75 Years",{"count":65,"type":66},32,"ESTIMATED","INTERVENTIONAL",[69],"PHASE1","This is a prospective, single-arm, open-label, exploratory clinical study of LCAR-HL30 in adult subjects with relapsed\u002Frefractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma.",[72,73],"Hodgkin's Lymphoma","Anaplastic Large Cell Lymphoma",[72,73],"2024-07-04",{"date":77,"type":78},"2024-07-10","ACTUAL",{"date":80,"type":66},"2024-07",{"date":82,"type":66},"2028-08",{"name":5,"class":6},1]